Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.45
OREX's Cash to Debt is ranked higher than
70% of the 1153 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. OREX: 2.45 )
OREX' s 10-Year Cash to Debt Range
Min: 2.21   Max: No Debt
Current: 2.45

Equity to Asset 0.11
OREX's Equity to Asset is ranked lower than
54% of the 957 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. OREX: 0.11 )
OREX' s 10-Year Equity to Asset Range
Min: -0.73   Max: 0.78
Current: 0.11

-0.73
0.78
F-Score: 5
Z-Score: 0.34
M-Score: 10.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -54.99
OREX's Operating margin (%) is ranked lower than
51% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.08 vs. OREX: -54.99 )
OREX' s 10-Year Operating margin (%) Range
Min: -107754.55   Max: -54.99
Current: -54.99

-107754.55
-54.99
Net-margin (%) -67.59
OREX's Net-margin (%) is ranked lower than
52% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.34 vs. OREX: -67.59 )
OREX' s 10-Year Net-margin (%) Range
Min: -105954.55   Max: -67.59
Current: -67.59

-105954.55
-67.59
ROE (%) -183.07
OREX's ROE (%) is ranked lower than
57% of the 1128 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.08 vs. OREX: -183.07 )
OREX' s 10-Year ROE (%) Range
Min: -235.61   Max: -42.04
Current: -183.07

-235.61
-42.04
ROA (%) -22.16
OREX's ROA (%) is ranked higher than
51% of the 1163 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. OREX: -22.16 )
OREX' s 10-Year ROA (%) Range
Min: -879.2   Max: -19.09
Current: -22.16

-879.2
-19.09
ROC (Joel Greenblatt) (%) -935.36
OREX's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 1158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.77 vs. OREX: -935.36 )
OREX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -193375   Max: -3874.08
Current: -935.36

-193375
-3874.08
Revenue Growth (3Y)(%) 73.50
OREX's Revenue Growth (3Y)(%) is ranked higher than
99% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. OREX: 73.50 )
OREX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 73.5
Current: 73.5

0
73.5
EBITDA Growth (3Y)(%) -23.00
OREX's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. OREX: -23.00 )
OREX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -8
Current: -23

EPS Growth (3Y)(%) -18.00
OREX's EPS Growth (3Y)(%) is ranked higher than
60% of the 813 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. OREX: -18.00 )
OREX' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.4   Max: 153.4
Current: -18

-55.4
153.4
» OREX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

OREX Guru Trades in Q1 2014

RS Investment Management 2,223,585 sh (+15.19%)
Paul Tudor Jones Sold Out
Steven Cohen 676,800 sh (-83.07%)
» More
Q2 2014

OREX Guru Trades in Q2 2014

RS Investment Management 2,179,142 sh (-2.00%)
» More
Q3 2014

OREX Guru Trades in Q3 2014

RS Investment Management 2,229,642 sh (+2.32%)
» More
Q4 2014

OREX Guru Trades in Q4 2014

RS Investment Management Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 41.90
OREX's P/B is ranked lower than
62% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. OREX: 41.90 )
OREX' s 10-Year P/B Range
Min: 0.85   Max: 45
Current: 41.9

0.85
45
P/S 16.06
OREX's P/S is ranked lower than
68% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.25 vs. OREX: 16.06 )
OREX' s 10-Year P/S Range
Min: 11.67   Max: 1495
Current: 16.06

11.67
1495
PFCF 39.50
OREX's PFCF is ranked higher than
83% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. OREX: 39.50 )
OREX' s 10-Year PFCF Range
Min: 27.63   Max: 42.63
Current: 39.5

27.63
42.63
POCF 42.11
OREX's POCF is ranked higher than
76% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.64 vs. OREX: 42.11 )
OREX' s 10-Year POCF Range
Min: 5.91   Max: 79.5
Current: 42.11

5.91
79.5
EV-to-EBIT -27.36
OREX's EV-to-EBIT is ranked higher than
62% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.16 vs. OREX: -27.36 )
OREX' s 10-Year EV-to-EBIT Range
Min: -28.6   Max: 2.5
Current: -27.36

-28.6
2.5
Current Ratio 7.11
OREX's Current Ratio is ranked higher than
91% of the 1023 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. OREX: 7.11 )
OREX' s 10-Year Current Ratio Range
Min: 3.3   Max: 19.3
Current: 7.11

3.3
19.3
Quick Ratio 7.07
OREX's Quick Ratio is ranked higher than
92% of the 1023 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. OREX: 7.07 )
OREX' s 10-Year Quick Ratio Range
Min: 3.3   Max: 19.3
Current: 7.07

3.3
19.3
Days Sales Outstanding 16.90
OREX's Days Sales Outstanding is ranked higher than
96% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.57 vs. OREX: 16.90 )
OREX' s 10-Year Days Sales Outstanding Range
Min: 8.2   Max: 16.9
Current: 16.9

8.2
16.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 62.80
OREX's Price/Net Cash is ranked higher than
82% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. OREX: 62.80 )
OREX' s 10-Year Price/Net Cash Range
Min: 1.01   Max: 50.5
Current: 62.8

1.01
50.5
Price/Net Current Asset Value 53.90
OREX's Price/Net Current Asset Value is ranked higher than
74% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. OREX: 53.90 )
OREX' s 10-Year Price/Net Current Asset Value Range
Min: 1   Max: 35.65
Current: 53.9

1
35.65
Price/Tangible Book 41.90
OREX's Price/Tangible Book is ranked lower than
60% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. OREX: 41.90 )
OREX' s 10-Year Price/Tangible Book Range
Min: 0.99   Max: 34.21
Current: 41.9

0.99
34.21
Price/Median PS Value 0.10
OREX's Price/Median PS Value is ranked higher than
100% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. OREX: 0.10 )
OREX' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 8.38
Current: 0.1

0.08
8.38
Earnings Yield (Greenblatt) -3.60
OREX's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1150 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. OREX: -3.60 )
OREX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.7   Max: 3901
Current: -3.6

-3.7
3901

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:JXS.Germany,
Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement with Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property strategy, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially significant markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 16 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
Steve Cohen Bets On Orexigen Ahead of FDA Approval Feb 01 2011 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 


More From Other Websites
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Orexigen Therapeutics, Inc. of... Apr 15 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Apr 14 2015
Law Offices of Howard G. Smith Reminds Investors of Orexigen Therapeutics, Inc. of the May 11, 2015... Apr 13 2015
OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Apr 10 2015
Orexigen Therapeutics to Speak at the Needham Healthcare Conference Apr 10 2015
Orexigen Therapeutics to Speak at the Needham Healthcare Conference Apr 10 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in... Apr 10 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Orexigen Therapeutics, Inc. of... Apr 10 2015
5 stocks to watch Apr 08 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Apr 06 2015
EQUITY ALERT: The Rosen Law Firm Reminds Orexigen Therapeutics, Inc. Investors of Important Deadline... Apr 03 2015
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Orexigen Therapeutics, Inc. Of... Apr 02 2015
Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money? Apr 02 2015
Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer Mar 30 2015
Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer Mar 30 2015
Leerink: Europe Deal Coming For Orexigen Therapeutics Mar 30 2015
OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Mar 27 2015
Barrack, Rodos & Bacine Has Filed an Investor Class Action Against Orexigen Therapeutics, Inc. Mar 27 2015
Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog Mar 27 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Mar 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK